Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study

BACKGROUND: Eribulin is a non-taxane, microtubule dynamics inhibitor that increases survival of patients with metastatic breast cancer. Although eribulin is well tolerated in patients with heavily pretreated disease, eribulin-induced liver dysfunction (EILD) can occur, resulting in treatment modific...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMC Cancer
Glavni autori: Kobayashi, Takayuki, Tomomatsu, Jyunichi, Fukada, Ippei, Shibayama, Tomoko, Teruya, Natsuki, Ito, Yoshinori, Iwase, Takuji, Ohno, Shinji, Takahashi, Shunji
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4936231/
https://ncbi.nlm.nih.gov/pubmed/27389013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2436-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items